Forecast
The analysts' average price target is €54.08 (+89.42%). The median is €55.60 (+94.75%).
| Buy |
Â
14 |
| Hold |
Â
0 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Pharvaris presents Deucrictibant ahead of market launch after strong phase‑III data
Pharvaris unveiled final plans for Deucrictibant at the Morgan Stanley Healthcare Conference. The oral HAE drug showed Phase‑III efficacy of 87% in HAE types 1 and 2 (83% in the extended population). The company is targeting U.S. approval for on‑demand treatment with a PDUFA target date of April 2027 and is preparing a prophylactic indication thereafter. Management highlighted a favorable safety profile versus competing oral therapies, plans to build a commercial organization (target: ~90 employees) and expects liquidity into mid‑2028 in the base case. Additional data from CREATE and an open‑label extension study are expected to be released in the coming months. » More on de.investing.com
Pharvaris shows phase‑III success: Deucrictibant reduces HAE attacks by 87%
At the Cantor Fitzgerald conference Pharvaris presented phase‑III data (CHAPTER‑3) showing an 87% reduction in hereditary angioedema attacks with the oral B2‑receptor antagonist Deucrictibant. The study included patients from six continents and used an extended‑release formulation that may explain the improved efficacy profile. Safety questions remain: two grade‑3 elevations in liver enzymes and one serious laryngeal event were reported, though the company considers the overall profile comparable to existing prophylactics. Pharvaris plans to launch the on‑demand treatment on April 8, 2025, and aims to file for approval for prophylaxis in the first half of 2025, supported by a targeted commercial platform for bradykinin‑mediated angioedemas. » More on de.investing.com
Pharvaris: oral HAE drug deucrictibant shows strong phase‑III data
Deucrictibant reduced HAE attacks by 87% in the phase‑III prophylaxis study in type‑1/ type‑2 patients (83% in the overall population) and replicated earlier results in a larger, global cohort. Pharvaris expects a PDUFA date for the on‑demand formulation on April 23 and plans to submit the regulatory application for the prophylaxis version in H1 2025. Two cases of elevated liver enzymes were reported but, according to management, are comparable to known risks; long‑term safety is being investigated in the open‑label extension study CHAPTER‑4. Commercially, the company intends to target treatment‑naive patients as well as users of ORLADEYO and injectable therapies. » More on de.investing.com
Pharvaris rises sharply after positive phase‑3 data for HAE drug
Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » More on de.investing.com
Pharvaris: Phase‑3 study of Deucrictibant XR meets primary endpoint and markedly reduces HAE attacks
Pharvaris reports that the Phase‑3 CHAPTER‑3 study of Deucrictibant XR met its primary endpoint for prevention of hereditary angioedema (HAE) attacks. A once‑daily 40 mg dose reduced the mean monthly attack rate across all three HAE types by 83% versus placebo and by 87% in HAE types 1 and 2; all secondary endpoints were also statistically significant. Protection began in the first week of treatment and was maintained over 24 weeks. Deucrictibant XR was well tolerated, with no treatment‑related serious adverse events. Pharvaris plans to use the CHAPTER‑3 data to support regulatory filings and intends to submit a New Drug Application to the FDA in the first half of 2027. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2022, Pharvaris Aktie has already paid €0.10 in dividends. The last payout was in July 2022.
Financials
In the last quarter, Pharvaris Aktie had revenue of €0 and net profit of -€47.41M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -47.41M | 27.67% |
| EBITDA | -49.99M | 34.33% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.02B |
Number of shares | 70.79M |
52-week high/low | €39.42 - €21.10 |
| Dividends | No |
Beta | -2.48 |
P/E ratio | -10.29 |
PEG ratio | -2.45 |
P/B ratio | 7.57 |
P/S ratio | 0.00 |
Company profile
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
| Name | Pharvaris Aktie |
| CEO | Berndt Modig |
| Headquarters | Zug,
zh Netherlands |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 02/05/2021 |
| Employees | 148 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | PHVS |
Frankfurt | 9EN.F |
DĂĽsseldorf | 9EN.DU |
MĂĽnchen | 9EN.MU |